Skip to Content
Merck
All Photos(1)

Key Documents

Z-005

Supelco

Zonisamide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C8H8N2O3S
CAS Number:
Molecular Weight:
212.23
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NS(CC1=NOC2=C1C=CC=C2)(=O)=O

InChI

1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

InChI key

UBQNRHZMVUUOMG-UHFFFAOYSA-N

General description

Zonisamide is a second-generation anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, and generalized tonic-clonic seizure. Zonisamide is marketed in the US under the trade name Zonegran®.

Application


  • Analysis of environmental samples: Instrument Response Standard for X-Ray Powder Diffraction was utilized for the dispersive magnetic micro solid phase extraction of pollutants in water samples and creams. This technique is vital for scientists engaged in environmental monitoring and contamination studies (Jalilian et al., 2019).

  • Food safety testing: The standard supported efficient extraction and determination methods for Rhodamine B in food samples, underscoring its importance in food safety and quality control labs focused on consumer health protection (Hu et al., 2019).

  • Advanced material characterization: A core-shell indium (III) sulfide@metal-organic framework nanocomposite used for the extraction of nitro-polycyclic aromatic hydrocarbons employs Instrument Response Standards to ensure accurate characterization of nanocomposite properties, critical for researchers developing new materials (Jia et al., 2018).


Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zonegran is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Y Chung et al.
New Zealand veterinary journal, 60(6), 357-359 (2012-05-30)
To evaluate the efficacy of zonisamide as a monotherapy in dogs with idiopathic epileptic seizure. The experiment was conducted on 10 dogs with idiopathic epilepsy that were treated at the Seoul National University Hospital for Animals. A diagnosis was conducted
Vedat Ali Yürekli et al.
Cellular and molecular neurobiology, 33(2), 205-212 (2012-12-12)
Parkinson's disease is an incurable progressive neurological condition caused by a degeneration of dopamine-producing cells characterized by motor and non-motor symptoms. The major mechanisms of the antiepileptic actions of ZNS are inhibition of voltage-gated Na(+) channel, T-type voltage-sensitive Ca(2+) channel
Zonisamide for the treatment of self-inflicted dermatoses related to impulse control disorders.
Maria José Tribó et al.
Archives of dermatology, 148(6), 762-764 (2012-06-20)
Zonisamide: no magic bullet.
Mitchell H Katz
Archives of internal medicine, 172(20), 1565-1565 (2012-10-17)
Kishore M Gadde et al.
Archives of internal medicine, 172(20), 1557-1564 (2012-11-14)
Obese individuals who have failed to achieve adequate weight loss with lifestyle changes have limited nonsurgical therapeutic options. We evaluated the efficacy and tolerability of zonisamide, an antiepileptic drug, for enhancing weight loss in obese patients receiving diet and lifestyle

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service